| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| John Allonce, Sikandar Khan, Brian Pulfor. Atypical Presentation of Ziprasidone-Induced Neuroleptic Malignant Syndrome: A Case Report. Journal of investigative medicine high impact case reports. vol 12. 2024-07-24. PMID:39044558. |
the patient had recently started on ziprasidone, a second-generation antipsychotic, leading to an atypical presentation of nms. |
2024-07-24 |
2024-07-26 |
Not clear |
| Yub Raj Sedhai, Alok Atreya, Prabin Phuyal, Soney Basnyat, Sagar Pokhre. Case Report: Ziprasidone induced neuroleptic malignant syndrome. F1000Research. vol 10. 2021-06-02. PMID:33763203. |
neuroleptic malignant syndrome (nms) is a well-recognized neurologic emergency. it presents with classic features including hyperthermia, autonomic instability, muscle hypertonia, and mental status changes. the syndrome is potentially fatal and is associated with significant morbidity due to complications such as rhabdomyolysis, acute kidney injury, and ventricular arrhythmias due to the trans-cellular electrolyte shift. nms is conventionally associated with the first-generation antipsychotic agents, however, has been described with the use of atypical and novel antipsychotics including ziprasidone. a case of nms with ziprasidone use at the therapeutic dose is reported here. |
2021-06-02 |
2023-08-13 |
Not clear |
| P Brittany Vickery, Lindsy Meadowcraft, Stephen B Vicker. Early detection of an atypical presentation of neuroleptic malignant syndrome: A case report. The mental health clinician. vol 7. issue 3. 2020-09-29. PMID:29955512. |
this article reports a case of suspected atypical nms in a patient following rapid conversion of ziprasidone to risperidone without titration. |
2020-09-29 |
2023-08-13 |
Not clear |
| Nicole M Schreiner, Samuel Windham, Andrew Barke. Atypical Neuroleptic Malignant Syndrome: Diagnosis and Proposal for an Expanded Treatment Algorithm: A Case Report. A & A case reports. vol 9. issue 12. 2018-05-17. PMID:28767476. |
symptoms of hyperthermia, altered mental status, dyskinesia, and autonomic instability (hypertension and tachycardia) coincided with promethazine administration, with rapid progression to fulminant nms with lead pipe rigidity after a single injection of intramuscular ziprasidone. |
2018-05-17 |
2023-08-13 |
Not clear |
| Praveen Tripathi, Hemika Agrawal, Priyanka Goyal, Sujita Kumar Ka. Olanzapine-induced neuroleptic malignant syndrome in a patient with bipolar affective disorder: Does quetiapine holds the solution? Industrial psychiatry journal. vol 22. issue 2. 2014-07-11. PMID:25013321. |
it is commonly encountered with the use of first generation antipsychotics, however cases of nms have been reported with the use of second generation antipsychotics like olanzapine, risperidone, paliperidone, aripiprazole, ziprasidone, amisulpride, quetiapine and clozapine, though the incidence of such reports is rare. |
2014-07-11 |
2023-08-13 |
Not clear |
| Julian N Trollor, Xiaohua Chen, Perminder S Sachde. Neuroleptic malignant syndrome associated with atypical antipsychotic drugs. CNS drugs. vol 23. issue 6. 2009-08-18. PMID:19480467. |
we used medline and embase to identify nms case reports and systematic reviews published to june 2008 related to the atypical antipsychotic drugs clozapine, olanzapine, risperidone, paliperidone, aripiprazole, ziprasidone, amisulpride and quetiapine. |
2009-08-18 |
2023-08-12 |
Not clear |
| Paul E Croarkin, Graham J Emslie, Taryn L Maye. Neuroleptic malignant syndrome associated with atypical antipsychotics in pediatric patients: a review of published cases. The Journal of clinical psychiatry. vol 69. issue 7. 2008-09-09. PMID:18572981. |
to retrospectively examine published cases of neuroleptic malignant syndrome (nms) in patients aged 18 and below who had been treated with atypical antipsychotics (clozapine, risperidone, olanzapine, quetiapine, ziprasidone, and aripiprazole). |
2008-09-09 |
2023-08-12 |
Not clear |
| Murat Eren Ozen, Mehmet Yumru, Haluk A Savas, Neslihan Cansel, Hasan Herke. Neuroleptic malignant syndrome induced by ziprasidone on the second day of treatment. The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry. vol 8. issue 1. 2007-05-02. PMID:17366349. |
although conventional neuroleptics are more frequently associated with nms, atypical antipsychotic drugs like ziprasidone may also be a cause. |
2007-05-02 |
2023-08-12 |
Not clear |
| Murat Eren Ozen, Mehmet Yumru, Haluk A Savas, Neslihan Cansel, Hasan Herke. Neuroleptic malignant syndrome induced by ziprasidone on the second day of treatment. The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry. vol 8. issue 1. 2007-05-02. PMID:17366349. |
this case is the earliest (second day of treatment) nms due to ziprasidone reported in the literature. |
2007-05-02 |
2023-08-12 |
Not clear |
| Murat Eren Ozen, Mehmet Yumru, Haluk A Savas, Neslihan Cansel, Hasan Herke. Neuroleptic malignant syndrome induced by ziprasidone on the second day of treatment. The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry. vol 8. issue 1. 2007-05-02. PMID:17366349. |
we describe a case of neuroleptic malignant syndrome (nms) associated with the use of ziprasidone. |
2007-05-02 |
2023-08-12 |
Not clear |
| Murat Eren Ozen, Mehmet Yumru, Haluk A Savas, Neslihan Cansel, Hasan Herke. Neuroleptic malignant syndrome induced by ziprasidone on the second day of treatment. The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry. vol 8. issue 1. 2007-05-02. PMID:17366349. |
the patient is a 24-year-old male with a history of schizophrenia who developed signs and symptoms of nms after 2 days of treatment with an 80-mg/day dose of orally administrated ziprasidone. |
2007-05-02 |
2023-08-12 |
Not clear |